Eli Lilly and Company (LLY) shares closed up 4.6% at $1,128.40, pushing the company's market capitalization to $1.07 trillion and making it the first pharmaceutical firm to cross the trillion-dollar threshold. The catalyst was the topline readout from ATTAIN-1, the pivotal Phase 3 trial of oral GLP-1 receptor agonist orforglipron in obesity, which showed mean weight loss of 14.7% at week 72 versus 2.1% on placebo and met all secondary endpoints with statistical significance.
The result positions orforglipron as the first oral once-daily GLP-1 with efficacy in the same range as injectable competitors. Tirzepatide (Zepbound) shows 22.5% weight loss at the same 72-week timepoint in real-world cohorts, but orforglipron's tablet formulation eliminates the supply-chain bottleneck of pre-filled injectors that has constrained the obesity market for two years. Dr. Daniel Skovronsky, Lilly's chief scientific officer, said on the conference call the company will file with the FDA in the third quarter and target a U.S. launch by the second half of 2027.
Competitive Dynamics
Novo Nordisk (NVO) shares fell 6.8% on the read-through, the steepest single-session decline since 2024. The Danish company is developing oral semaglutide (CagriSema oral) with topline expected in late 2026, but the orforglipron data set a higher bar. Pfizer (PFE) — which discontinued danuglipron in April 2025 — was unchanged, while Roche (RHHBY) ADRs slipped 1.4% on competitive concerns for its CT-388 program. Structure Therapeutics (GPCR) declined 11.2%.
Total addressable obesity-market estimates have been revised: BofA's Tim Anderson lifted his 2030 GLP-1 sales-pool forecast to $215 billion from $185 billion, with oral formulations now expected to capture 41% mix versus the prior 28%. Lilly's own guidance implies orforglipron peak sales of $30-40 billion, on top of Mounjaro/Zepbound's combined $54 billion FY2026 trajectory.